Epidermal growth factor receptor, somatostatin and Bcl-2 in human pancreatic tumor xenografts: An immunohistochemical study

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Xenografted human pancreatic tumors (5 ductal adenocarcinomas, 1 leiomyosarcoma, altogether 26 samples) were investigated about their immunohistochemical expression of epidermal growth factor receptor (EGFR), somatostatin (SS) and bcl-2 protein. The expression of the EGFR varied from tumor to tumor. One originally negative carcinoma became immunoreactive during passagings, one tumor has lost its early positive expression, and in 3 cancer lines a phenotypically constant pattern was seen. SS immunoreactivity was practically absent in all tumor samples. Concerning bcl-2 expression, different staining patterns were observed among the carcinomas, but the leiomyosarcoma has retained its strong positivity during xenograftings. In the PZX-5 carcinoma line that was originally negative, the one-month Sandostatin treatment induced the strong expression of bcl-2 protein suggesting a development of an acquired resistance against programmed cell death in this tumor.

Original languageEnglish
Pages (from-to)146-151
Number of pages6
JournalPathology and Oncology Research
Volume5
Issue number2
DOIs
Publication statusPublished - Jun 1999

Fingerprint

Somatostatin
Epidermal Growth Factor Receptor
Heterografts
Neoplasms
Leiomyosarcoma
Carcinoma
Heterologous Transplantation
Octreotide
Proteins
Adenocarcinoma
Cell Death
Staining and Labeling

Keywords

  • Bcl-2
  • Pancreas tumor
  • Somatostatin
  • Xenograft

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

@article{0c3801f4285e447b9e577c63604018c8,
title = "Epidermal growth factor receptor, somatostatin and Bcl-2 in human pancreatic tumor xenografts: An immunohistochemical study",
abstract = "Xenografted human pancreatic tumors (5 ductal adenocarcinomas, 1 leiomyosarcoma, altogether 26 samples) were investigated about their immunohistochemical expression of epidermal growth factor receptor (EGFR), somatostatin (SS) and bcl-2 protein. The expression of the EGFR varied from tumor to tumor. One originally negative carcinoma became immunoreactive during passagings, one tumor has lost its early positive expression, and in 3 cancer lines a phenotypically constant pattern was seen. SS immunoreactivity was practically absent in all tumor samples. Concerning bcl-2 expression, different staining patterns were observed among the carcinomas, but the leiomyosarcoma has retained its strong positivity during xenograftings. In the PZX-5 carcinoma line that was originally negative, the one-month Sandostatin treatment induced the strong expression of bcl-2 protein suggesting a development of an acquired resistance against programmed cell death in this tumor.",
keywords = "Bcl-2, Pancreas tumor, Somatostatin, Xenograft",
author = "A. Zalatnai",
year = "1999",
month = "6",
doi = "10.1053/paor.1999.0176",
language = "English",
volume = "5",
pages = "146--151",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "2",

}

TY - JOUR

T1 - Epidermal growth factor receptor, somatostatin and Bcl-2 in human pancreatic tumor xenografts

T2 - An immunohistochemical study

AU - Zalatnai, A.

PY - 1999/6

Y1 - 1999/6

N2 - Xenografted human pancreatic tumors (5 ductal adenocarcinomas, 1 leiomyosarcoma, altogether 26 samples) were investigated about their immunohistochemical expression of epidermal growth factor receptor (EGFR), somatostatin (SS) and bcl-2 protein. The expression of the EGFR varied from tumor to tumor. One originally negative carcinoma became immunoreactive during passagings, one tumor has lost its early positive expression, and in 3 cancer lines a phenotypically constant pattern was seen. SS immunoreactivity was practically absent in all tumor samples. Concerning bcl-2 expression, different staining patterns were observed among the carcinomas, but the leiomyosarcoma has retained its strong positivity during xenograftings. In the PZX-5 carcinoma line that was originally negative, the one-month Sandostatin treatment induced the strong expression of bcl-2 protein suggesting a development of an acquired resistance against programmed cell death in this tumor.

AB - Xenografted human pancreatic tumors (5 ductal adenocarcinomas, 1 leiomyosarcoma, altogether 26 samples) were investigated about their immunohistochemical expression of epidermal growth factor receptor (EGFR), somatostatin (SS) and bcl-2 protein. The expression of the EGFR varied from tumor to tumor. One originally negative carcinoma became immunoreactive during passagings, one tumor has lost its early positive expression, and in 3 cancer lines a phenotypically constant pattern was seen. SS immunoreactivity was practically absent in all tumor samples. Concerning bcl-2 expression, different staining patterns were observed among the carcinomas, but the leiomyosarcoma has retained its strong positivity during xenograftings. In the PZX-5 carcinoma line that was originally negative, the one-month Sandostatin treatment induced the strong expression of bcl-2 protein suggesting a development of an acquired resistance against programmed cell death in this tumor.

KW - Bcl-2

KW - Pancreas tumor

KW - Somatostatin

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=0032815246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032815246&partnerID=8YFLogxK

U2 - 10.1053/paor.1999.0176

DO - 10.1053/paor.1999.0176

M3 - Article

C2 - 10393368

AN - SCOPUS:0032815246

VL - 5

SP - 146

EP - 151

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 2

ER -